Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Mayne Pharma nears...

    Mayne Pharma nears deal for Teva assets

    Written by savita thakur thakur Published On 2016-06-28T09:59:43+05:30  |  Updated On 28 Jun 2016 9:59 AM IST
    Mayne Pharma nears deal for Teva assets

    Australian pharmaceutical company Mayne Pharma Group Ltd is nearing a deal to purchase assets from Teva Pharmaceuticals worth around $600 million, a person familiar with the matter said.


    The deal is the last of several large divestitures of U.S. assets required by regulators for the approval of Teva's planned $40 billion acquisition of Allergan Plc's generic drugs portfolio. Teva announced the proposed deal last July.


    The U.S. Federal Trade Commision is reviewing Teva's divestiture agreements and is expected to provide approval for the deal with Allergan as early as next month, the source said.


    The combination of the two pharmaceutical would be completed soon thereafter, the source added.


    In all, Teva has agreed to sell assets to Dr. Reddy's Laboratories, Impax Laboratories, Sagent Pharmaceuticals, and Cadila Healthcare, as well as a number of private companies.


    The U.S. asset divestitures are worth around $2 billion in total, added the source, who spoke on condition of anonymity because the deal talks are private.


    Teva and Mayne were not immediately available for comment.


    The Australian Financial Review first reported Mayne's plans to acquire the Teva assets.


    Teva's proposed acquisition of Allergan's generics portfolio would solidify the Israeli company's position as the world's largest generic manufacturer at a time when scale is increasingly crucial to negotiating favorable terms with payers.


    For Allergan, the transaction will focus its business on innovative, brand-name drugs and provide a massive cash pile for future acquisitions.


    In Europe, Teva is in the process of finding buyers for assets including its UK and Irish generics business, which is expected to be worth upward of $1.3 billion, the source said.


    The European divestitures are expected to be finished by fall of 2016, the source said. They will not effect the timeline of the completion of the Allergan deal, the person added.


    Teva worked with investment bank Greenhill & Co Inc and law firm Kirkland & Ellis LLP on the transactions.

    AllerganAustralian pharmaCadila HealthcareDr Reddy'sGreenhill & CoImpaxMayne PharmaSagent PharmaTeva
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok